(Q24242896)

2

0 references

Pierre Chue

3

0 references

Mark Fenton

4

0 references

Vikram Palanisamy

5

0 references

Winson Wong

6

0 references

Jun Xia

Cochrane Database of Systematic Reviews

7

0 references

publication date

17 October 2007

0 references

published in

0 references

cites work

Loxapine versus haloperidol parenterally in acute psychosis with agitation. A double-blind study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Efficacy of loxapine in the treatment of paranoid schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Cocaine and amphetamine use in patients with psychiatric illness: a randomized trial of typical antipsychotic continuation or discontinuation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: effects of antipsychotic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

The assessment of neuroleptogenic extrapyramidal syndroms in psychopharmacological research (author's transl)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Clinical and plasma level characteristics of intramuscular and oral loxapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Loxapine versus thioridazine in the treatment of organic psychosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Statistics notes. Trials randomised in clusters

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

New dimensions in the pharmacologic treatment of schizophrenia and related psychoses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Bias in treatment assignment in controlled clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

The unit of analysis error in studies about physicians' patient care behavior

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Issues in the meta-analysis of cluster randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Randomised controlled trials: sampling

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

What is meant by intention to treat analysis? Survey of published randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Clinical implications of Brief Psychiatric Rating Scale scores

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

What does the PANSS mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Empirical evidence of bias. Dimensions of methodological quality associated with estimates of treatment effects in controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Which atypical antipsychotic.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Loxapine for schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD001943.PUB2

Rapid tranquilization: a comparison of thiothixene with loxapine.

21 January 2018

1 reference

12 December 2020

1 reference

12 December 2020

Loxapine: a double-blind comparison with chlorpromazine in acute schizophrenic patients

1 reference

12 December 2020

Evaluation of two dose levels of loxapine succinate in chronic schizophrenia

1 reference

12 December 2020

The EEG effects of dibenzoxazepines (loxapine succinate) as compared to CPZ: EEG changes as drug side effects.

1 reference

12 December 2020

[The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use]

1 reference

12 December 2020

Problems and profits of cross-national collaborative studies

1 reference

12 December 2020

A Double-Blind Comparison of Loxapine Succinate and Trifluoperazine in Newly Admitted Schizophrenic Patients

1 reference

12 December 2020

Factors which can make patients difficult to treat.

1 reference

12 December 2020

Loxapine succinate: a comparative study with chlorpromazine

1 reference

12 December 2020

A double-blind comparative trial of loxapine and trifluoperazine in acute and chronic schizophrenic patients

1 reference

12 December 2020

Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia

1 reference

12 December 2020

Loxapine succinate: a new neuroleptic

1 reference

12 December 2020

Methods for evaluating area-wide and organisation-based interventions in health and health care: a systematic review

1 reference

12 December 2020

A controlled double-blind comparison between loxapine and haloperidol in acute newly hospitalized schizophrenic patients

1 reference

12 December 2020

New antipsychotics in schizophrenia: the French experience

1 reference

12 December 2020

A controlled evaluation of loxitane in seventy-five adolescent schizophrenic patients

1 reference

12 December 2020

Is loxapine more effective than chlorpromazine in paranoid schizophrenia?

1 reference

12 December 2020

Statistical analysis of the activity of loxapine and thioridazine in a double-blind study

1 reference

12 December 2020

Loxapine in Newly Admitted Chronic Schizophrenic Patients

1 reference

12 December 2020

Consistency and similarity of drug-EEG responses in chronic schizophrenic patients

1 reference

12 December 2020

Loxapine: a controlled evaluation in chronic schizophrenic patients

1 reference

12 December 2020

Loxapine succinate: a controlled double-blind study in chronic schizophrenia

1 reference

12 December 2020

Treatment of acute schizophrenia with loxapine succinate (Loxitane) in a controlled study with chlorpromazine

1 reference

12 December 2020

Loxapine succinate in the treatment of chronic schizophrenia

1 reference

12 December 2020

A two year trial of loxapine succinate in chronic psychotic patients

1 reference

12 December 2020

A comparison of parenteral loxapine and haloperidol in hostile and aggressive acutely schizophrenic patients.

1 reference

12 December 2020

Loxapine succinate: a double-blind comparison with haloperidol and placebo in acute schizophrenics

1 reference

12 December 2020

Evaluation of loxapine succinate in chronic schizophrenia

1 reference

12 December 2020

Detecting skewness from summary information

1 reference

12 December 2020

The efficacy and safety of loxapine succinate in the treatment of schizophrenia: a comparative study with thiothixene

1 reference

12 December 2020

Response of borderline patients to loxapine and chlorpromazine

1 reference

12 December 2020

A double-blind comparison of loxitane--loxapine succinate and trifluoperazine hydrochloride in chronic schizophrenic patients

1 reference

12 December 2020

A double-blind comparison between loxapine and haloperidol by parenteral route in acute schizophrenia

1 reference

12 December 2020

Effects of gradual decrease and discontinuation of neuroleptics on clinical condition and tardive dyskinesia [proceedings]

1 reference

12 December 2020

Loxapine versus chlorpromazine in paranoid schizophrenia: a double-blind study

1 reference

12 December 2020

Effectiveness of loxapine succinate in acute schizophrenia: a comparative study with thiothixene

1 reference

12 December 2020

Loxapine succinate: a controlled double-blind study in schizophrenia

1 reference

12 December 2020

A controlled double-blind comparison between loxapine succinate and chlorpromazine in acute newly hospitalized schizophrenic patients

1 reference

12 December 2020

Risperidone versus Conventional Antipsychotics for Schizophrenia and Schizoaffective Disorder : Symptoms, Quality of Life and Resource Use under Customary Clinical Care

1 reference

12 December 2020

Effects of neuroleptic adjustment on clinical condition and tardive dyskinesia in schizophrenic patients

1 reference

12 December 2020

Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations

1 reference

12 December 2020

The relationship of pharmacology to side effects

1 reference

12 December 2020